title: Long-term results of the use of oxybutynin for the treatment of axillary hyperhidrosis.
abstract: BACKGROUND
  Axillary hyperhidrosis (AH) is a common disease, with a significant impact on quality of life (QOL). Good short-term results are reported with oxybutynin, but longer follow-up data are lacking. We evaluated its effectiveness in a large series of patients who were not surgically treated and who had at least 6 months of follow-up.
  
  
  METHODS
  From September 2007 to September 2013, 431 consecutive patients were enrolled in "pharmacological first" protocol for treatment of AH with oxybutynin. Thirty-four patients were lost to follow-up, and data are available for 397 patients treated for at least 6 weeks. Data at the start of the protocol, 6 weeks after beginning treatment, and at final visit were analyzed.
  
  
  RESULTS
  One hundred fourteen patients (28.7%) did not improve and were referred for surgery (sympathectomy). Eight patients (2.01%) presented significant side effects (e.g. dry mouth) and discontinued therapy. Twenty-six patients (9.4%) preferred surgery over pharmacologic treatment. Sixty-two patients have not yet been under treatment for 6 months. The 181 patients with more than 6 months of follow-up (median: 17 months, range: 6-72) were analyzed as follows: 82.9% of patients presented moderate or great improvement in AH and 89% of patients presented improvement in other sites of hyperhidrosis after a median of 17 months.
  
  
  CONCLUSIONS
  In patients with good initial response to oxybutynin, >80% presented moderate or great improvement in axillary and in other sites of excessive sweating. Results were particularly better in women and those who presented better QOL after 6 weeks.
authors: Hospital Israelita Albert Einstein-HIAE, São Paulo, São Paulo, Brazil; Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo-HCFMUSP, São Paulo, São Paulo, Brazil.
authors: Nelson
authors: N
authors: Wolosker
authors: Hospital Israelita Albert Einstein-HIAE, São Paulo, São Paulo, Brazil. Electronic address: dr.marcelo@consultoriovasculares.med.br.
authors: Marcelo Passos
authors: MP
authors: Teivelis
authors: Hospital Israelita Albert Einstein-HIAE, São Paulo, São Paulo, Brazil.
authors: Mariana
authors: M
authors: Krutman
authors: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo-HCFMUSP, São Paulo, São Paulo, Brazil.
authors: Rafael Pessanha
authors: RP
authors: de Paula
authors: Hospital Israelita Albert Einstein-HIAE, São Paulo, São Paulo, Brazil.
authors: Paulo
authors: P
authors: Kauffman
authors: Hospital Israelita Albert Einstein-HIAE, São Paulo, São Paulo, Brazil; Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo-HCFMUSP, São Paulo, São Paulo, Brazil.
authors: José Ribas M
authors: JR
authors: de Campos
authors: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo-HCFMUSP, São Paulo, São Paulo, Brazil.
authors: Pedro
authors: P
authors: Puech-Leão
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001365:Axilla; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006945:Hyperhidrosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage*; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage; D010349:Patient Compliance; D017060:Patient Satisfaction; D012189:Retrospective Studies; D013546:Sweating / Q000187:drug effects*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin